{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=16&q=hormone+receptor-positive", "query": { "q": "hormone receptor-positive", "condition": "Breast Cancer", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 678, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=17&q=hormone+receptor-positive&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=15&q=hormone+receptor-positive&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T10:29:48.626Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03361800", "title": "Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer", "Invasive Breast Cancer", "ER-Negative PR-Negative HER2-Negative Breast Cancer" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5, "start_date": "2018-11-28", "completion_date": "2019-10-11", "has_results": false, "last_update_posted_date": "2024-03-25", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03361800" }, { "nct_id": "NCT02107703", "title": "A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 669, "start_date": "2014-07-22", "completion_date": "2027-12", "has_results": true, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 43, "location_summary": "Jonesboro, Arkansas • Springdale, Arkansas • La Jolla, California + 36 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02107703" }, { "nct_id": "NCT02102490", "title": "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 132, "start_date": "2014-06-10", "completion_date": "2018-10-22", "has_results": true, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 27, "location_summary": "Sedona, Arizona • Tucson, Arizona • San Francisco, California + 22 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02102490" }, { "nct_id": "NCT02291913", "title": "Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Toremifine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2014-12-18", "completion_date": "2019-01-31", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 8, "location_summary": "Fort Myers, Florida • Hollywood, Florida • Pensacola, Florida + 5 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Terre Haute", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02291913" }, { "nct_id": "NCT04190056", "title": "Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-03-11", "completion_date": "2023-06-15", "has_results": true, "last_update_posted_date": "2023-08-31", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04190056" }, { "nct_id": "NCT02760030", "title": "Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor and/or Progesterone Receptor Positive", "HER2/Neu Negative", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Aromatase Inhibitors", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "FEMALE", "summary": "65 Years and older · Female only" }, "enrollment_count": 14, "start_date": "2017-02-16", "completion_date": "2025-08-31", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 3, "location_summary": "Edgewood, Kentucky • Cleveland, Ohio • Columbus, Ohio", "locations": [ { "city": "Edgewood", "state": "Kentucky" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02760030" }, { "nct_id": "NCT02246621", "title": "A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 493, "start_date": "2014-11-06", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 20, "location_summary": "Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02246621" }, { "nct_id": "NCT00666822", "title": "Compliance to a Hormone Therapy Regimen in Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "compliance monitoring", "type": "BEHAVIORAL" }, { "name": "medical chart review", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 178, "start_date": "2007-12", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-02-05", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666822" }, { "nct_id": "NCT04215146", "title": "A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pelareorep", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Oncolytics Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2020-06-10", "completion_date": "2025-06", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 18, "location_summary": "Miami, Florida • Urbana, Illinois • Indianapolis, Indiana + 13 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04215146" }, { "nct_id": "NCT02779751", "title": "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2016-11-14", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-15T10:29:48.626Z", "location_count": 7, "location_summary": "Springdale, Arkansas • San Francisco, California • Aurora, Colorado + 4 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02779751" } ] }